252 related articles for article (PubMed ID: 27909342)
1. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
2. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
[TBL] [Abstract][Full Text] [Related]
4. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Dmitrieva EA; Nikitin EA; Ignatova AA; Vorobyev VI; Poletaev AV; Seregina EA; Voronin KA; Polokhov DM; Maschan AA; Novichkova GA; Panteleev MA; Ptushkin VV
J Thromb Haemost; 2020 Oct; 18(10):2672-2684. PubMed ID: 32511880
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
7. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
[TBL] [Abstract][Full Text] [Related]
10. Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.
Jones JA; Hillmen P; Coutre S; Tam C; Furman RR; Barr PM; Schuster SJ; Kipps TJ; Flinn IW; Jaeger U; Burger JA; Cheng M; Ninomoto J; James DF; Byrd JC; O'Brien SM
Br J Haematol; 2017 Jul; 178(2):286-291. PubMed ID: 28397242
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
13. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
16. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
17. Risk of Major Bleeding with Ibrutinib.
Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
[TBL] [Abstract][Full Text] [Related]
18. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
Georgantopoulos P; Yang H; Norris LB; Bennett CL
Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
[TBL] [Abstract][Full Text] [Related]
20. Whole blood ristocetin-induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
Nakajima Y; Nogami K; Yada K; Ogiwara K; Furukawa S; Shimonishi N; Shima M
Haemophilia; 2019 May; 25(3):e174-e179. PubMed ID: 30866149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]